So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes ...

We are holding steady to our fair value estimate and wide moat rating for Pfizer PFE following first-quarter results that largely matched our expectations. The company is tracking well to meet its ...

・Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over ...